alternative scheduling of sunitinib and newer therapies for rcc: an update from asco 2017
Published 4 years ago • 132 plays • Length 7:29Download video MP4
Download video MP3
Similar videos
-
4:00
dosing and combinations of sunitinib vis-à-vis alternative therapies for rcc
-
0:40
dr. robert dreicer on an alternate sunitinib schedule in metastatic renal cell carcinoma
-
3:00
adjuvant sunitinib in renal cell carcinoma
-
5:53
key rcc data from asco gu 2017: tkis, immunotherapy, alternative scheduling and qol
-
3:15
current concepts in adjuvant therapy for rcc from asco gu 2017
-
3:04
my approach to dosing schedules for sunitinib
-
6:26
current data on rcc therapy: sunitinib dosing, combination therapy and more
-
6:19
current data on rcc therapy: sunitinib dosing, combination therapy and more
-
9:20
scheduling strategies in rcc
-
7:39
sequencing therapy for metastatic rcc: an evidence-based analysis
-
10:06
lenvatinib and pembrolizumab compared to sunitinib for advanced renal cell carcinoma
-
5:09
comparz trial and alternate sunitinib dosing schedule in metastatic renal cell carcinoma
-
3:36
sunitinib vs cabozantinib, crizotinib, or savolitinib for metastatic papillary rcc
-
4:57
sunitinib or pd-1 as frontline rcc therapy: a conceptual review
-
7:14
dosing sunitinib and pazopanib in renal cell carcinoma
-
1:56
sunitinib for treating high-risk rcc
-
1:24
dr. figlin on sunitinib for patients with rcc
-
6:57
dosing schedule of sunitinib in renal cell carcinoma
-
8:43
optimizing the upfront treatment of metastatic renal cell carcinoma